ReleaseWire Connect

The report covers the global ink additives market and further segments the market on the basis of type, process, application, and region. The market data for these types is given with respect to volume (kilotons) and value ($million). The global market value of ink additives was estimated to be about $629.02 million in 2013 and is projected to grow at a CAGR 5.78% between 2014 and 2019. The data mentioned in the report are based on the global demand for ink additives.

The wireless portable medical device market is expected to grow at a rapid pace due to growing income levels, and increasing prevalence of chronic and lifestyle disorders such as diabetes, respiratory, blood and cardiovascular diseases. A growing population coupled with high income levels and awareness about wellness and fitness are some of the factors driving the market growth. Further, integration of various wireless technologies with portable devices and initiatives from various governments have led rural areas to adopt advanced medical services, thereby boosting the wireless portable medical device industry.

The global casing & cementation hardware market exhibits a lucrative growth potential of about 8% for the next five years. The growth of this market is propelled by rising concerns about safety & environment and the increasing capital expenditure in E&P operations being carried out across the globe. The market is further driven by factors such as increasing drilling activities. The high growth potential in emerging markets and increased use of casing & cementation hardware in shale mining provide new growth opportunities to players in the casing & cementation hardware market. Rising number of ageing and maturing wells & increasing E&P activities for search of new fields is bound to increase the market of casing & cementation hardware, slated to be valued around $2.5 billion by 2019. North America, with its increased focus on technological innovations in the oil & gas industry, is expected to experience the highest revenue growth in the next five years.

The Talent management software market is expected to grow from $5,270.3 million in 2014 to $11,367.0 million by 2019, at an estimated Compound Annual Growth Rate (CAGR) of 16.6% from 2014 to 2019. The Talent Management software (TMS) market is fast gaining traction primarily due to the increasing complexities and increasing trend of workforce mobility. TMS refers to the various solutions designed by using modern technology to plan, deliver, evaluate and manage an organization structure all the way from strategy formulation to employee learning. Talent management acts as an information system that manages company budget, tracks performance of the learners, resource hiring, training and development and overall functionality of organization.

The report "Oral Mucositis – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Oral Mucositis. Oral mucositis is a common complication of chemotherapy & it is caused by a virus, fungus or bacteria, immune deficiency and medications. One of the main causes of mucositis is high dose cancer therapy. Oral mucositis affects almost 0.5 million persons each year. Treatment is based on the cause of symptoms. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

The report "Paraganglioma (Glomus Jugulare Tumor) – Pipeline Review, H1 2015 provides comprehensive information on the therapeutic development for Paraganglioma (Glomus Jugulare Tumor). Paraganglioma is an unusual tumor that develop in cells of peripheral nervous system. Paraganglioma is mainly noncancerous tumor of the middle ear. Most people with paraganglioma grow only one tumor in their lifetime. The cause of paraganglioma (glomus jugulare tumor) is unknown.

The report "Helicobacter Pylori Infections – Pipeline Review, H1 2015? provides comprehensive information on the therapeutic development for Helicobacter Pylori Infections. Helicobacter pylori (H. pylori) are a bacterium that is commonly found in the stomach. The most common way of Helicobacter pylori infection is either oral-to-oral or fecal-to-oral contact. It is found in about two-thirds of the world's population. Helicobacter pylori cause peptic ulcers and stomach cancer. The infection is more common in packed living conditions with poor cleanliness.

The report "Amyloidosis – Pipeline Review, H1 2015 provides comprehensive information on the therapeutic development for Amyloidosis. Amyloidosis is a rare but serious condition in which an abnormal protein builds up in tissues and organs. Two thirds of patients with amyloidosis are male and less than 5% of patients are under 40 years of age. The cause of primary amyloidosis is unknown and it can lead to conditions that include Carpal tunnel syndrome, Heart muscle damage, Kidney failure, Intestinal malabsorption, Liver swelling, Nerve problems, Nephrotic syndrome and Orthostatic hypotension.

The report "Iron Deficiency Anemia – Pipeline Review, H1 2015 provides comprehensive information on the therapeutic development for Iron Deficiency Anemia. Iron deficiency anemia is a common type of anemia and occurs when body does not have sufficient mineral iron. Insufficient dietary iron, impaired iron absorption, bleeding or loss of body iron in the urine may be the cause. Iron deficiency anemia signs and symptoms include fatigue, leg cramps on climbing stairs, craving ice, poor scholastic performance, dysphagia with solid foods, reduced resistance to infection, cold intolerance, altered behavior and comorbid cardiac or pulmonary disease.

The report "Thrombocythaemia Myelofibrosis – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Thrombocythaemia Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocythaemia Myelofibrosis and special features on late-stage and discontinued projects.